1. Market Research
  2. > All Companies
  3. > Hodgkin Lymphoma - Pipeline Review, H2 2015

Hodgkin Lymphoma - Pipeline Review, H2 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 322 pages

Hodgkin Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hodgkin Lymphoma - Pipeline Review, H2 2015’, provides an overview of the Hodgkin Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hodgkin Lymphoma - Pipeline Review, H2 2015
Table of Contents
Table of Contents 2

Introduction 8
Global Markets Direct Report Coverage 8
Hodgkin Lymphoma Overview 9
Therapeutics Development 10
Pipeline Products for Hodgkin Lymphoma - Overview 10
Pipeline Products for Hodgkin Lymphoma - Comparative Analysis 11
Hodgkin Lymphoma - Therapeutics under Development by Companies 12
Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 15
Hodgkin Lymphoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Hodgkin Lymphoma - Products under Development by Companies 20
Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 24
Hodgkin Lymphoma - Companies Involved in Therapeutics Development 25
4SC AG 25
Acetylon Pharmaceuticals, Inc. 26
Actinium Pharmaceuticals, Inc. 27
ADC Therapeutics Sarl 28
Affimed Therapeutics AG 29
Aptose Biosciences Inc. 30
Arbutus Biopharma Corporation 31
AVEO Pharmaceuticals, Inc. 32
Bellicum Pharmaceuticals, Inc. 33
Biogenomics Limited 34
Bristol-Myers Squibb Company 35
Celgene Corporation 36
Cell Medica Limited 37
Cellular Biomedicine Group, Inc. 38
Constellation Pharmaceuticals, Inc. 39
Curis, Inc. 40
Gamida Cell Ltd. 41
Gilead Sciences, Inc. 42
Incyte Corporation 43
Johnson and Johnson 44
Merck and Co., Inc. 45
Millennium Pharmaceuticals, Inc. 46
Mirati Therapeutics Inc. 47
Molecular Templates Inc. 48
NantKwest, Inc. 49
Novartis AG 50
Ono Pharmaceutical Co., Ltd. 51
Pfizer Inc. 52
Pharmacyclics, Inc. 53
Philogen S.p.A. 54
Seattle Genetics, Inc. 55
Selvita SA 56
Sigma-Tau S.p.A. 57
Spectrum Pharmaceuticals, Inc. 58
Stemline Therapeutics, Inc. 59
Syndax Pharmaceuticals, Inc. 60
TG Therapeutics, Inc. 61
Theravectys SA 62
Hodgkin Lymphoma - Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Target 64
Assessment by Mechanism of Action 69
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
abexinostat hydrochloride - Drug Profile 77
acalisib - Drug Profile 80
ADCT-301 - Drug Profile 81
AFM-13 - Drug Profile 82
Alocrest - Drug Profile 83
aNK Program - Drug Profile 85
APTO-253 - Drug Profile 88
azacitidine - Drug Profile 90
BMS-986016 - Drug Profile 94
BPX-501 - Drug Profile 95
brentuximab vedotin - Drug Profile 97
CBM-C30.1 - Drug Profile 103
Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 104
Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile 105
Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 106
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 107
Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile 108
CMD-003 - Drug Profile 109
CPI-0610 - Drug Profile 111
CUDC-907 - Drug Profile 112
Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile 114
Dendritic Cell Therapy for Oncology - Drug Profile 115
entinostat - Drug Profile 116
Ferritarg - Drug Profile 120
ficlatuzumab - Drug Profile 121
haNK Program - Drug Profile 124
INCB-39110 - Drug Profile 126
INCB-40093 - Drug Profile 128
Indimitecan - Drug Profile 129
Indotecan hydrochloride - Drug Profile 130
interferon alfa-2b (recombinant) - Drug Profile 132
Iomab-B - Drug Profile 133
ixazomib citrate - Drug Profile 135
JNJ-40346527 - Drug Profile 139
MK-2206 - Drug Profile 141
mocetinostat - Drug Profile 144
Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 147
Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 148
NiCord - Drug Profile 149
nivolumab - Drug Profile 150
NSC-678515 - Drug Profile 157
panobinostat - Drug Profile 158
pembrolizumab - Drug Profile 164
pevonedistat hydrochloride - Drug Profile 173
procarbazine hydrochloride - Drug Profile 175
radretumab - Drug Profile 176
Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile 178
resminostat - Drug Profile 179
ricolinostat - Drug Profile 184
RP-323 - Drug Profile 186
ruxolitinib phosphate - Drug Profile 187
SEL-24B489 - Drug Profile 192
SL-101 - Drug Profile 193
SL-501 - Drug Profile 194
temsirolimus - Drug Profile 195
TGR-1202 - Drug Profile 197
TKM-PLK1 - Drug Profile 199
Vaccine for EBV Associated Cancer - Drug Profile 201
Hodgkin Lymphoma - Recent Pipeline Updates 202
Hodgkin Lymphoma - Dormant Projects 299
Hodgkin Lymphoma - Discontinued Products 302
Hodgkin Lymphoma - Product Development Milestones 303
Featured News and Press Releases 303
Appendix 317
Methodology 317
Coverage 317
Secondary Research 317
Primary Research 317
Expert Panel Validation 317
Contact Us 317
Disclaimer 318

List of Tables
Number of Products under Development for Hodgkin Lymphoma, H2 2015 14
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2015 15
Number of Products under Development by Companies, H2 2015 17
Number of Products under Development by Companies, H2 2015 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2015 19
Comparative Analysis by Late Stage Development, H2 2015 20
Comparative Analysis by Clinical Stage Development, H2 2015 21
Comparative Analysis by Early Stage Development, H2 2015 22
Comparative Analysis by Unknown Stage Development, H2 2015 23
Products under Development by Companies, H2 2015 24
Products under Development by Companies, H2 2015 (Contd..1) 25
Products under Development by Companies, H2 2015 (Contd..2) 26
Products under Development by Companies, H2 2015 (Contd..3) 27
Products under Investigation by Universities/Institutes, H2 2015 28
Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2015 29
Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015 30
Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015 31
Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2015 32
Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015 33
Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc., H2 2015 34
Hodgkin Lymphoma - Pipeline by Arbutus Biopharma Corporation, H2 2015 35
Hodgkin Lymphoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 36
Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015 37
Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H2 2015 38
Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 39
Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2015 40
Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H2 2015 41
Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 42
Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015 43
Hodgkin Lymphoma - Pipeline by Curis, Inc., H2 2015 44
Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2015 45
Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 46
Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2015 47
Hodgkin Lymphoma - Pipeline by Johnson and Johnson, H2 2015 48
Hodgkin Lymphoma - Pipeline by Merck and Co., Inc., H2 2015 49
Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 50
Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2015 51
Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H2 2015 52
Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H2 2015 53
Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2015 54
Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 55
Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2015 56
Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015 57
Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H2 2015 58
Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 59
Hodgkin Lymphoma - Pipeline by Selvita SA, H2 2015 60
Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2015 61
Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 62
Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2015 63
Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H2 2015 64
Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015 65
Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2015 66
Assessment by Monotherapy Products, H2 2015 67
Number of Products by Stage and Target, H2 2015 69
Number of Products by Stage and Mechanism of Action, H2 2015 74
Number of Products by Stage and Route of Administration, H2 2015 78
Number of Products by Stage and Molecule Type, H2 2015 80
Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 206
Hodgkin Lymphoma - Dormant Projects, H2 2015 303
Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2015 304
Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2015 305
Hodgkin Lymphoma - Discontinued Products, H2 2015 306

List of Figures
Number of Products under Development for Hodgkin Lymphoma, H2 2015 14
Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H2 2015 15
Number of Products under Development by Companies, H2 2015 16
Number of Products under Investigation by Universities/Institutes, H2 2015 19
Comparative Analysis by Late Stage Development, H2 2015 20
Comparative Analysis by Clinical Stage Development, H2 2015 21
Comparative Analysis by Early Stage Products, H2 2015 22
Assessment by Monotherapy Products, H2 2015 67
Number of Products by Top 10 Targets, H2 2015 68
Number of Products by Stage and Top 10 Targets, H2 2015 68
Number of Products by Top 10 Mechanism of Actions, H2 2015 73
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 73
Number of Products by Routes of Administration, H2 2015 77
Number of Products by Stage and Routes of Administration, H2 2015 77
Number of Products by Top 10 Molecule Types, H2 2015 79
Number of Products by Stage and Top 10 Molecule Types, H2 2015 79

Companies Mentioned
4SC AG
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed Therapeutics AG
Aptose Biosciences Inc.
Arbutus Biopharma Corporation
AVEO Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
Biogenomics Limited
Bristol-Myers Squibb Company
Celgene Corporation
Cell Medica Limited
Cellular Biomedicine Group, Inc.
Constellation Pharmaceuticals, Inc.
Curis, Inc.
Gamida Cell Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Johnson and Johnson
Merck and Co., Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Molecular Templates Inc.
NantKwest, Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmacyclics, Inc.
Philogen S.p.A.
Seattle Genetics, Inc.
Selvita SA
Sigma-Tau S.p.A.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Syndax Pharmaceuticals, Inc.
TG Therapeutics, Inc.
Theravectys SA

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Neurosurgical Products - Pipeline Review, 2015

Neurosurgical Products - Pipeline Review, 2015

  • $ 4 000
  • Company report
  • October 2015
  • by Global Data

Neurosurgical Products - Pipeline Review, 2015 Summary GlobalData's Medical Devices sector report, “Neurosurgical Products - Pipeline Review, 2015" provides an overview of Neurosurgical Products currently ...

EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024

EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024

  • $ 3 995
  • Company report
  • November 2015
  • by Global Data

EpiCast Report: Hepatocellular Carcinoma - Epidemiology Forecast to 2024 Summary Hepatocellular carcinoma (HCC) is a common type of primary liver cancer that arises from the hepatocytes in the liver. HCC ...

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015

  • $ 2 500
  • Company report
  • December 2015
  • by Global Markets Direct

B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2015’, provides an overview of the B-Cell Non-Hodgkin Lymphoma’s ...


Download Unlimited Documents from Trusted Public Sources

Novartis - Investor Report, January 2016

  • January 2016
    77 pages
  • Pharmaceutical  

    Company Sales F...  

    Oncology  

  • Europe  

    World  

View report >

Manulife - Company Report, January 2016

  • January 2016
    4 pages
  • Pathology  

    Cancer  

  • China  

    United States  

    Asia  

View report >

Amgen - Investor Report, January 2016

  • January 2016
    37 pages
  • Neurological Di...  

    Neurology  

    Oncology  

  • World  

View report >

Related Market Segments :

Cancer
Pharmaceutical
Oncology
Therapeutics
Therapy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.